Automatic Immunoassay Analyzer Market Research, 2033
The global automatic immunoassay analyzer market size was valued at $12.3 billion in 2023, and is projected to reach $51.4 billion by 2033, growing at a CAGR of 15.3% from 2024 to 2033. Increasing demand for precise and efficient diagnostic testing, advancements in technology leading to higher accuracy and faster results, the growing prevalence of chronic and infectious diseases, and the expansion of healthcare infrastructure globally are the major factors which drives the market growth.
Market Introduction and Definition
An automatic immunoassay analyzer is a laboratory instrument designed to streamline and automate the process of conducting immunoassays, which are tests that detect the presence or quantity of specific substances in biological samples based on the reaction between antigens and antibodies. These analyzers efficiently handle various stages of the immunoassay workflow, including sample preparation, reagent mixing, incubation, and result detection. By automating these tasks, these instruments enhance the precision, speed, and overall efficiency of diagnostic testing, making them invaluable in clinical laboratories for tasks such as measuring hormones, proteins, and other biomarkers in blood or other bodily fluids.
Key Takeaways
The automatic immunoassay analyzer market share study covers 20 countries. The research includes a segment analysis of each country in terms of value for the projected period.
More than 1, 500 product literatures, industry releases, annual reports, and other such documents of major automatic immunoassay analyzer industry participants along with authentic industry journals, trade associations' releases, and government websites have been reviewed for generating high-value industry insights.
The study integrated high-quality data, professional opinions and analysis, and critical independent perspectives. The research approach is intended to provide a balanced view of global markets and to assist stakeholders in making educated decisions in order to achieve their most ambitious growth objectives.
Key Market Dynamics
The rising prevalence of infectious and chronic diseases such as cancer, autoimmune disorders, and growing geriatric population around the globe have resulted into high volumes of diagnostic tests drives the automatic immunoassay analyzer market growth. Rising demand toward lab automation and popularity of these products, due to immense funding related to R&D activities and wide clinical applications further led to surge in the demand for automated immunoassay analyzers. In addition, rise in technological advancements in the field of efficient lab equipment will further fuel the global automatic immunoassay analyzer market size. Several pharmaceutical and biologics firms are increasingly using these detection mechanisms for drug discovery and development purposes.
Moreover, the rise in demand for rapid diagnostic testing at point-of-care settings, such as clinics, emergency departments, and pharmacies is thereby driving the growth during automatic immunoassay analyzer market forecast period. Automated immunoassay analyzers designed for POCT offer rapid turnaround times, minimal sample volume requirements, and user-friendly interfaces, making them ideal for decentralized testing environments.
However, the dearth of skilled professionals and the unavailability of healthcare providers in the emerging and underdeveloped regions is expected to hamper the market. Furthermore, advancements in technology lead to higher throughput and accuracy, increasing demand for faster diagnostic results, and expanding applications in drug development and research which provides automatic immunoassay analyzer market opportunity. In addition, the shift towards personalized medicine and the integration of automation in laboratories to improve efficiency are further contributing to market expansion.
Rise in Prevalence of Diabetes to boost the Automatic Immunoassay Analyzer Market
According to the International Diabetes Federation, in 2021, there were 537 million people worldwide living with diabetes. By 2030, this number is projected to increase to 643 million, and by 2045, it is expected to reach 783 million. This upward trend emphasizes the growing global health challenge posed by diabetes, necessitating advancements in diagnostic technologies and healthcare solutions. Automatic immunoassay analyzers play a pivotal role in addressing this challenge by providing accurate and efficient diagnostic capabilities. These analyzers automate the process of detecting biomarkers such as blood glucose levels, crucial for diagnosing and managing diabetes. The rise in prevalence of diabetes led to the rise in demand for automated diagnostic solutions such as immunoassay analyzers. This trend highlights opportunities for innovation and market expansion in the automatic immunoassay analyzer sector.
Market Segmentation
The automatic immunoassay analyzer market is segmented into product, application, end user, and region. On the basis of the product, the market is segmented into immunofluorescence, chemiluminescence, enzyme linked fluorescent system, and others. By application, the market is classified into infectious diseases, endocrinology, drug monitoring, chronic diseases, allergy testing, and others. By end user, the market is divided into hospitals, diagnostic laboratories, pharmaceutical and biotechnology companies, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Regional/Country Market Outlook
North America leads the automatic immunoassay analyzer market share owing to advanced healthcare systems, high healthcare expenditure, and a strong emphasis on technological innovation. In addition, adoption of automated diagnostic technologies in clinical laboratories and research institutions further supports the market growth in this region. However, Asia-Pacific showcases rapid market expansion, fueled by rising healthcare awareness, increasing disease prevalence, and expanding healthcare access. In addition, countries such as China, India, and Japan are key growth markets due to their large population bases and ongoing healthcare modernization efforts.
According to American Medical Association, the health spending in the U.S. increased by 4.1% in 2022 ($4.4 trillion) . This higher expenditure supports the adoption of advanced medical technologies, including automated analyzers, across hospitals, clinics, and diagnostic laboratories in the North America region.
Industry Trends
According to the United Nations International Children's Emergency Fund (UNICEF) in 2023, there were over 1, 400 cases of pneumonia per 100, 000 children, or 1 case per 71 children every year, with the greatest incidence occurring in South Asia. The high incidence of pneumonia, particularly in children in South Asia, drives the critical need for accurate and rapid diagnostic tools such as immunoassay analyzers thereby propelling the market growth.
In 2022, according to the World Health Organization (WHO) , there were 20 million new cancer cases. The number of people who were alive within 5 years following a cancer diagnosis was 53.5 million. The high incidence of cancer necessitates continuous monitoring and accurate diagnostics for effective treatment and management thereby driving the demand for automatic immunoassay analyzers.
Competitive Landscape
The major players operating in the automatic immunoassay analyzer market include Abbott, Meril Life Sciences Pvt. Ltd., BioMerieux, Arlington Scientific, F. Hoffmann-La Roche Ltd, ?Carolina Liquid Chemistries, Becton Dickinson and Company, Bio-Rad Laboratories, Inc, PerkinElmer Inc., and AESKU.GROUP GmbH.
Recent Key Strategies and Developments in the Automatic Immunoassay Analyzer Industry
In February 2023, Epitope Diagnostics, Inc. launched its fully automated chemiluminescent immunoassay analyzers (ECL25 and ECL100) together with panel kits of routine and niche chemiluminescence immunoassay tests covering different clinical areas. This launch aims to enhance diagnostic capabilities across different medical fields.
Key Sources Referred
- National Center for Biotechnology and Information (NCBI)
- Centers for Medicare & Medicaid Services (CMS)
- National Health Service (NHS)
- Australian Government Department of Health and Aged Care
- Government of Canada's Health and Wellness
- Ministry of Health and Family Welfare (MoHFW)
- National Health Mission (NHM)
- Ayushman Bharat - Health and Wellness Centres (AB-HWCs)
- Centers for Disease Control and Prevention (CDC)
- Food and Drug Administration (FDA)
- National Institutes of Health (NIH)
- World Health Organization (WHO)
Key Benefits for Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the automatic immunoassay analyzer market analysis from 2024 to 2033 to identify the prevailing automatic immunoassay analyzer market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the automatic immunoassay analyzer market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global automatic immunoassay analyzer market trends, key players, market segments, application areas, and market growth strategies.
Automatic Immunoassay Analyzer Market Report Highlights
| Aspects | Details |
 Market Size By 2033 | USD 51.4 Billion |
 Growth Rate | CAGR of 15.3% |
 Forecast period | 2024 - 2033 |
 Report Pages | 228 |
 By Product |
|
 By Application |
|
 By End User |
|
 By Region |
|
 Key Market Players | F. Hoffmann-La Roche Ltd, PerkinElmer Inc., Abbott, Arlington Scientific, AESKU.GROUP GmbH , Bio-Rad Laboratories, Inc, BioMerieux, Carolina Liquid Chemistries, Becton Dickinson and Company,, Meril Life Sciences Pvt. Ltd. |
The total market value of automatic immunoassay analyzer market is $12.3 billion in 2023.
The market value of automatic immunoassay analyzer market in 2033 is $51.4 billion.
The forecast period for automatic immunoassay analyzer market is 2024 to 2033.
Growth factors include advancements in technology, rising prevalence of chronic and infectious diseases, increasing demand for precise diagnostics, and the expansion of healthcare infrastructure.
Applications include routine screening, disease diagnosis, monitoring treatment efficacy, and conducting research in clinical laboratories.
An automatic immunoassay analyzer is a laboratory instrument designed to perform immunoassays with minimal manual intervention, offering high precision and efficiency in diagnostic testing.
Loading Table Of Content...
